Education
About Us
Working with TipRanks
Follow Us
Bolt Biotherapeutics (BOLT)
NASDAQ:BOLT
BOLT Stock Chart & Stats
$5.44
-$0.02(-3.16%)
At close: 4:00 PM EST
$5.44
-$0.02(-3.16%)
Day’s Range― - ―
52-Week Range$4.41 - $12.59
Previous CloseN/A
Volume72.19K
Average Volume (3M)29.18K
Market Cap
$9.67M
Enterprise Value-$305.28K
Total Cash (Recent Filing)$31.91M
Total Debt (Recent Filing)$23.59M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Apr 01, 2026EPS Estimate
-5.63Last Dividend Ex-Date
Aug 29, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-3.72
Shares Outstanding1,919,441
10 Day Avg. Volume31,146
30 Day Avg. Volume29,181
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)7.14
Price to Sales (P/S)53.13
P/FCF Ratio-6.66
Enterprise Value/Market Cap-0.03
Enterprise Value/Revenue-0.06
Enterprise Value/Gross Profit-0.07
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$41.00Price Target Upside653.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBolt recorded a net loss of $3.72 per share, which was narrower than the estimated net loss of $5.05 per share.
Financial StabilityBolt ended with $38.8M in cash and equivalents, supporting an operational runway extending into 2027.
Innovative Drug DevelopmentBolt Biotherapeutics' lead asset, BDC-4182, differentiates itself by using a toll-like receptor (TLR) 7/8 agonist instead of a cytotoxic warhead.
Bears Say
Market ConditionsBuyer appetite and valuations for immuno-oncology assets remain weak, and a deal may not provide enough capital to materially extend runway ahead of BDC-4182.
Regulatory RisksRisks include delays in anticipated data releases for BDC-4182, negative efficacy data, inability to receive FDA approval, superior data from competitors, and possible dilution risk.
Workforce ReductionBolt is reducing its workforce by approximately 50%, which shall extend its cash runway into 2027.
Bolt Biotherapeutics News
BOLT FAQ
What was Bolt Biotherapeutics’s price range in the past 12 months?
Bolt Biotherapeutics lowest stock price was $4.41 and its highest was $12.59 in the past 12 months.
What is Bolt Biotherapeutics’s market cap?
Bolt Biotherapeutics’s market cap is $9.67M.
When is Bolt Biotherapeutics’s upcoming earnings report date?
Bolt Biotherapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 108 days.
How were Bolt Biotherapeutics’s earnings last quarter?
Bolt Biotherapeutics released its earnings results on Nov 12, 2025. The company reported -$3.72 earnings per share for the quarter, beating the consensus estimate of -$5.676 by $1.956.
Is Bolt Biotherapeutics overvalued?
According to Wall Street analysts Bolt Biotherapeutics’s price is currently Undervalued.
Does Bolt Biotherapeutics pay dividends?
Bolt Biotherapeutics pays a Quarterly dividend of $0.09 which represents an annual dividend yield of N/A. See more information on Bolt Biotherapeutics dividends here
What is Bolt Biotherapeutics’s EPS estimate?
Bolt Biotherapeutics’s EPS estimate is -5.63.
How many shares outstanding does Bolt Biotherapeutics have?
Bolt Biotherapeutics has 1,919,441 shares outstanding.
What happened to Bolt Biotherapeutics’s price movement after its last earnings report?
Bolt Biotherapeutics reported an EPS of -$3.72 in its last earnings report, beating expectations of -$5.676. Following the earnings report the stock price went down -2.495%.
Which hedge fund is a major shareholder of Bolt Biotherapeutics?
Currently, no hedge funds are holding shares in BOLT
Company Description
Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
BOLT Stock 12 Month Forecast
Average Price Target
$41.00
▲(653.68% Upside)
Technical Analysis
Ownership Overview
5.54% Insiders
6.57% Mutual Funds
35.32% Other Institutional Investors
50.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---